Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus

• Published in: The Journal of infectious diseases Vol. 217; no. 6; pp. 887 - 896
• Main Authors: Kiso, Maki, Lopes, Tiago J S, Yamayoshi, Seiya, Ito, Mutsumi, Yamashita, Makoto, Nakajima, Noriko, Hasegawa, Hideki, Neumann, Gabriele, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 05.03.2018
• Subjects: Amides - administration & dosage; Amides - therapeutic use; Animals; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - therapeutic use; Female; Immunocompromised Host; Influenza A Virus, H1N1 Subtype - drug effects; Lung - pathology; Lung - virology; Major and Brief Reports; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase - antagonists & inhibitors; Nucleic Acid Synthesis Inhibitors - administration & dosage; Nucleic Acid Synthesis Inhibitors - therapeutic use; Orthomyxoviridae Infections - drug therapy; Orthomyxoviridae Infections - virology; Oseltamivir - administration & dosage; Oseltamivir - therapeutic use; Pyrazines - administration & dosage; Pyrazines - therapeutic use; Zanamivir - administration & dosage; Zanamivir - analogs & derivatives; Zanamivir - therapeutic use

Treatment of immunocompromised, influenza virus-infected patients with the viral neuraminidase inhibitor oseltamivir often leads to the emergence of drug-resistant variants. Combination therapy with compounds that target different steps in the viral life cycle may improve treatment outcomes and redu...